# 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

> **NCT00976937** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 319 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Lixisenatide (AVE0010)
- **DRUG:** Lixisenatide Placebo
- **DEVICE:** Pen auto-injector
- **DRUG:** Sitagliptin
- **DRUG:** Sitagliptin Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00976937
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976937, "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00976937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*